News

Solasia is currently completing a Phase I study of darinaparsin in Japan and South Korea to treat patients with relapsed and refractory peripheral T-cell lymphoma (hereinafter "PTCL"). Solasia

The new partnership with Janssen brings to nine the number of pharmaceutical companies around CQDM’s table, increasing the financial leverage that partners generate together. Thanks to CQDM’s unique

This NIH/National Institute of Neurological Disorders and Stroke (NINDS) award will support NIH’s Drug Manufacturing and Formulation Program (DMFP), which is a component of the Blueprint Neurotherapeutics Network

Dipraglurant, a novel small molecule inhibitor of the metabotropic glutamate receptor 5, has shown promise in the treatment of levodopa-induced dyskinesia and dystonia in Parkinson’s disease. Dipraglurant has

OnCore would continue as a subsidiary of Tekmira, and the licensing agreement for NVP018 between NeuroVive and OnCore will remain in force following the merger as the combined

If approved, paliperidone palmitate will be the first and only long-acting atypical antipsychotic that has a dosing schedule of just four times a year. Schizophrenia is a complex

The approval follows an expedited review and positive opinion issued by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in November 2014. In

In order to further develop several series of Orexin-1 selective inhibitors, Evotec will apply its drug discovery platform with C4XD. Activation of the orexin-1 receptor in the brain

Cosentyx 300mg is the first and only interleukin-17A (IL-17A) inhibitor to be approved in Europe providing a new first-line biologic treatment option for these patients. At present, all